Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season |
| |
| Institution: | 1. Central Virology Laboratory, Chaim Sheba Medical Center, Israel Ministry of Health, Tel-Hashomer, Ramat Gan, Israel;2. Israel Center for Disease Control, Ministry of Health, Tel Hashomer, Ramat Gan, Israel;3. School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;4. School of Public Health, University of Haifa, Haifa, Israel;1. Serum Institute of India Private Limited, 212/2, Hadapsar, Pune, India;2. PATH, PO Box 900922, Seattle, WA 98109, USA;1. Epidemiology and Disease Control Division, Ministry of Health, Singapore;2. Communicable Disease Division, Ministry of Health, Singapore;3. National Public Health Laboratory, Ministry of Health, Singapore;1. Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital and Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region;2. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region;3. Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong Special Administrative Region;1. School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA;2. Department of Pediatrics, Division of Infectious Diseases, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA;1. School of Public Health, Curtin University, Kent Street, Bentley, Western Australia 6152, Australia;2. Communicable Disease Control Directorate, Department of Health Western Australia, 189 Royal Street, Perth, Western Australia 6004, Australia;3. Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia 6027, Australia;4. School of Pathology and Laboratory Medicine, University of Western Australia, 35 Stirling Ave, Crawley, Western Australia 6008, Australia;1. Istituto Superiore di Sanità, Rome, Italy;2. Dipartimento Scienze biomediche ed oncologia umana, Università degli Studi di Bari Aldo Moro, Bari, Italy;3. Dipartimento di Scienze biomediche per la salute, Università degli Studi di Milano, Milan, Italy;4. Governo della Prevenzione e tutela sanitaria, Regione Lombardia, Milan, Italy;5. SeREMI ASL AL, Servizio Riferimento Regionale, Epidemiologia Malattie Infettive, Alessandria, Italy;6. Ospedale “Amedeo di Savoia”- Torino, Italy;7. Servizio Sanità pubblica, D. G. Sanità e Politiche sociali, Regione Emilia-Romagna, Bologna, Italy;8. Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, Università degli Studi di Parma, Italy |
| |
| Abstract: | BackgroundThe 2017–2018 influenza season in Israel was characterized by the predominance of influenza B Yamagata, with a lesser circulation of influenza A(H1N1)pdm09 and influenza A(H3N2). We estimated vaccine effectiveness (VE) of the inactivated influenza vaccine which was selected for use that season.MethodsEnd-of-season VE and 95% confidence intervals (CI) against laboratory-confirmed influenza-like illness (ILI) were estimated by means of the test-negative design. Age-specific VE analysis was carried out using a moving age interval.ResultsSpecimen were obtained from 1,453 community ILI patients; 610 (42.0%) were influenza-positive, among which 69.7% were B, 17.2% A(H1N1)pdm09 and 13.4% A(H3N2). A 98.6% of molecularly characterized influenza B belonged to the Yamagata lineage. Of the sampled individuals, 1320 were suitable for VE analysis. Of those vaccinated, 90.6% received the inactivated trivalent influenza vaccine (TIV) containing a Victoria lineage influenza B-like virus. VE against influenza A differed by age, with the highest VE of 72.9% (95%CI 31.9–89.2%) observed in children 0.5–14 years old, while all ages VE was 46.6% (95%CI 10.4–68.2%). All ages VE against influenza B was 23.2% (95%CI ?10.1–46.4%) with age-specific analysis showing non-significant VE estimates. Utilizing a moving age interval of 15 years, afforded a detailed age-specific insight into influenza VE against the influenza viruses circulating during the 2017–2018 season.ConclusionsThe moderate-high 2017–2018 influenza A VE among children and adolescents, supports seasonal influenza vaccination at a young age. The low VE against influenza B in Israel, is most likely the result of influenza B/TIV-mismatch. |
| |
| Keywords: | Influenza Influenza vaccine Vaccine effectiveness |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
